UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Held Back By Slow EPS Growth

UBS maintains a 'Buy' on Johnson & Johnson (NYSE: JNJ) price target lowered from $71 to $70.

Analyst, Rajeev Jashnani, said, "In our view, stock has been held back by slow EPS growth while addition of SYST complicates 2013 outlook. Latter point should resolve after deal closes & a revised 2012 outlook is provided (incl. share repo plans). If JNJ can approach Street EPS for 2013 (+7% growth), stock ultimately should regain traction as underlying revenue growth is good; that said, 2013 is not right around the corner yet, either."

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $64.22 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Deutsche Bank Downgrades Workday (WDAY) to Hold
• Grocery Outlet Holding (GO) PT Raised to $11.50 at UBS
• Spruce Biosciences, Inc. (SPRB) PT Lowered to $104 at Guggenheim